Indian Journal of Surgery-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2213723, encodeId=45132213e23cd, content=审稿速度:1.0 偏重的研究方向：泌尿系肿瘤 经验分享：很垃圾的期刊，不愧是阿三创办的 写了篇前列腺癌的临床研究，回顾性分析 貌似就一个审稿人，给拒了，理由是建议投稿至泌尿外科或者肿瘤科的期刊 然后编辑就给了拒稿 明明官网写的清清楚楚，泌尿外科和肿瘤学的文章都收，还能以这个理由拒稿 给的审稿人还不是泌尿外科或者肿瘤科的人，编辑部也是极品了 审稿人也是个der，不是你领域的文章你拒绝审稿邀请不就行了，还给我拒稿了，浪费我那么长时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1eff9108850, createdName=ms9000001144988530, createdTime=Sun Jul 07 12:30:45 CST 2024, time=2024-07-07, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1199342, encodeId=fb8b1199342bf, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：普通外科学 经验分享：9月份投稿，12月返修，次年1月接受，2月风出版，**版权就免版面费，人生中第一篇sci,非常激动和感激。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eafe5507087, createdName=ms1000000343499485, createdTime=Fri Mar 04 10:59:07 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188584, encodeId=63ae1188584d3, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ecdd5512474, createdName=ms8000000861535702, createdTime=Thu Jan 27 14:02:15 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101836, encodeId=73f1110183634, content=讨论中局限性怎么撰写？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101835, encodeId=375a110183584, content=是否需要在讨论中说明文章局限性？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080259, encodeId=f4ca1080259c3, content=各位大咖，我投了一篇稿，要求提供伦理委员会证明，有没有模板之类的？谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/bjkbwbHXEDKYj70DA8G0QLwo33kNdOmR0oUwVuP0FibVF8qssNC8nADf0OTkicaMU806LQVe15sPw0bBoVrbQBWg/132, createdBy=63c55215809, createdName=ms3330713541554951, createdTime=Wed Dec 15 10:48:09 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=507298, encodeId=214d50e29847, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：印度杂志，比较好中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=426, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96ff1604274, createdName=xietingfeng124, createdTime=Mon Nov 03 20:12:00 CST 2014, time=2014-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=543696, encodeId=5253543696fc, content=只要能保住SCI源的期刊,就可以了.以后学校采用CiteScore来计算的话,就不用怕了. 一方面CiteScore引用的杂志宽得多,这个杂志肯定在其中,另外,对小杂志有好处,大家差剧没这么大, 希望学校采用CiteScore, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=354, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=Lin_ling, createdTime=Fri Jul 14 18:54:00 CST 2017, time=2017-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=531108, encodeId=a6db5311081d, content=审稿速度:12.0 | 投稿命中率:50.0 经验分享：2016年3月份开始投稿，大修1次，小修1次，2016年年底ACCEPT, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=220, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2019/01/06/7a77f76154188e6264228df7693515cf.jpg, createdBy=cb4a1680684, createdName=xiayu0001, createdTime=Mon Dec 26 21:49:00 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=521934, encodeId=ad9052193462, content=审稿一年了，还是Under review，要等到什么时候啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=410, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11f51627008, createdName=yezhifanfan, createdTime=Mon May 02 15:04:00 CST 2016, time=2016-05-02, status=1, ipAttribution=)]

2024-07-07 ms9000001144988530 来自湖北省

审稿速度:1.0
偏重的研究方向：泌尿系肿瘤
经验分享：很垃圾的期刊，不愧是阿三创办的
写了篇前列腺癌的临床研究，回顾性分析
貌似就一个审稿人，给拒了，理由是建议投稿至泌尿外科或者肿瘤科的期刊
然后编辑就给了拒稿
明明官网写的清清楚楚，泌尿外科和肿瘤学的文章都收，还能以这个理由拒稿
给的审稿人还不是泌尿外科或者肿瘤科的人，编辑部也是极品了
审稿人也是个der，不是你领域的文章你拒绝审稿邀请不就行了，还给我拒稿了，浪费我那么长时间

1 0

[GetPortalCommentsPageByObjectIdResponse(id=2213723, encodeId=45132213e23cd, content=审稿速度:1.0 偏重的研究方向：泌尿系肿瘤 经验分享：很垃圾的期刊，不愧是阿三创办的 写了篇前列腺癌的临床研究，回顾性分析 貌似就一个审稿人，给拒了，理由是建议投稿至泌尿外科或者肿瘤科的期刊 然后编辑就给了拒稿 明明官网写的清清楚楚，泌尿外科和肿瘤学的文章都收，还能以这个理由拒稿 给的审稿人还不是泌尿外科或者肿瘤科的人，编辑部也是极品了 审稿人也是个der，不是你领域的文章你拒绝审稿邀请不就行了，还给我拒稿了，浪费我那么长时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1eff9108850, createdName=ms9000001144988530, createdTime=Sun Jul 07 12:30:45 CST 2024, time=2024-07-07, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1199342, encodeId=fb8b1199342bf, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：普通外科学 经验分享：9月份投稿，12月返修，次年1月接受，2月风出版，**版权就免版面费，人生中第一篇sci,非常激动和感激。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eafe5507087, createdName=ms1000000343499485, createdTime=Fri Mar 04 10:59:07 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188584, encodeId=63ae1188584d3, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ecdd5512474, createdName=ms8000000861535702, createdTime=Thu Jan 27 14:02:15 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101836, encodeId=73f1110183634, content=讨论中局限性怎么撰写？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101835, encodeId=375a110183584, content=是否需要在讨论中说明文章局限性？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080259, encodeId=f4ca1080259c3, content=各位大咖，我投了一篇稿，要求提供伦理委员会证明，有没有模板之类的？谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/bjkbwbHXEDKYj70DA8G0QLwo33kNdOmR0oUwVuP0FibVF8qssNC8nADf0OTkicaMU806LQVe15sPw0bBoVrbQBWg/132, createdBy=63c55215809, createdName=ms3330713541554951, createdTime=Wed Dec 15 10:48:09 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=507298, encodeId=214d50e29847, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：印度杂志，比较好中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=426, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96ff1604274, createdName=xietingfeng124, createdTime=Mon Nov 03 20:12:00 CST 2014, time=2014-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=543696, encodeId=5253543696fc, content=只要能保住SCI源的期刊,就可以了.以后学校采用CiteScore来计算的话,就不用怕了. 一方面CiteScore引用的杂志宽得多,这个杂志肯定在其中,另外,对小杂志有好处,大家差剧没这么大, 希望学校采用CiteScore, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=354, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=Lin_ling, createdTime=Fri Jul 14 18:54:00 CST 2017, time=2017-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=531108, encodeId=a6db5311081d, content=审稿速度:12.0 | 投稿命中率:50.0 经验分享：2016年3月份开始投稿，大修1次，小修1次，2016年年底ACCEPT, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=220, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2019/01/06/7a77f76154188e6264228df7693515cf.jpg, createdBy=cb4a1680684, createdName=xiayu0001, createdTime=Mon Dec 26 21:49:00 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=521934, encodeId=ad9052193462, content=审稿一年了，还是Under review，要等到什么时候啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=410, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11f51627008, createdName=yezhifanfan, createdTime=Mon May 02 15:04:00 CST 2016, time=2016-05-02, status=1, ipAttribution=)]

2022-03-04 ms1000000343499485

审稿速度:3.0 | 投稿命中率:75.0
偏重的研究方向：普通外科学
经验分享：9月份投稿，12月返修，次年1月接受，2月风出版，**版权就免版面费，人生中第一篇sci,非常激动和感激。

49 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2213723, encodeId=45132213e23cd, content=审稿速度:1.0 偏重的研究方向：泌尿系肿瘤 经验分享：很垃圾的期刊，不愧是阿三创办的 写了篇前列腺癌的临床研究，回顾性分析 貌似就一个审稿人，给拒了，理由是建议投稿至泌尿外科或者肿瘤科的期刊 然后编辑就给了拒稿 明明官网写的清清楚楚，泌尿外科和肿瘤学的文章都收，还能以这个理由拒稿 给的审稿人还不是泌尿外科或者肿瘤科的人，编辑部也是极品了 审稿人也是个der，不是你领域的文章你拒绝审稿邀请不就行了，还给我拒稿了，浪费我那么长时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1eff9108850, createdName=ms9000001144988530, createdTime=Sun Jul 07 12:30:45 CST 2024, time=2024-07-07, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1199342, encodeId=fb8b1199342bf, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：普通外科学 经验分享：9月份投稿，12月返修，次年1月接受，2月风出版，**版权就免版面费，人生中第一篇sci,非常激动和感激。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eafe5507087, createdName=ms1000000343499485, createdTime=Fri Mar 04 10:59:07 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188584, encodeId=63ae1188584d3, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ecdd5512474, createdName=ms8000000861535702, createdTime=Thu Jan 27 14:02:15 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101836, encodeId=73f1110183634, content=讨论中局限性怎么撰写？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101835, encodeId=375a110183584, content=是否需要在讨论中说明文章局限性？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080259, encodeId=f4ca1080259c3, content=各位大咖，我投了一篇稿，要求提供伦理委员会证明，有没有模板之类的？谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/bjkbwbHXEDKYj70DA8G0QLwo33kNdOmR0oUwVuP0FibVF8qssNC8nADf0OTkicaMU806LQVe15sPw0bBoVrbQBWg/132, createdBy=63c55215809, createdName=ms3330713541554951, createdTime=Wed Dec 15 10:48:09 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=507298, encodeId=214d50e29847, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：印度杂志，比较好中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=426, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96ff1604274, createdName=xietingfeng124, createdTime=Mon Nov 03 20:12:00 CST 2014, time=2014-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=543696, encodeId=5253543696fc, content=只要能保住SCI源的期刊,就可以了.以后学校采用CiteScore来计算的话,就不用怕了. 一方面CiteScore引用的杂志宽得多,这个杂志肯定在其中,另外,对小杂志有好处,大家差剧没这么大, 希望学校采用CiteScore, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=354, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=Lin_ling, createdTime=Fri Jul 14 18:54:00 CST 2017, time=2017-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=531108, encodeId=a6db5311081d, content=审稿速度:12.0 | 投稿命中率:50.0 经验分享：2016年3月份开始投稿，大修1次，小修1次，2016年年底ACCEPT, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=220, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2019/01/06/7a77f76154188e6264228df7693515cf.jpg, createdBy=cb4a1680684, createdName=xiayu0001, createdTime=Mon Dec 26 21:49:00 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=521934, encodeId=ad9052193462, content=审稿一年了，还是Under review，要等到什么时候啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=410, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11f51627008, createdName=yezhifanfan, createdTime=Mon May 02 15:04:00 CST 2016, time=2016-05-02, status=1, ipAttribution=)]

2022-01-27 ms8000000861535702

审稿速度:3.0 | 投稿命中率:75.0
经验分享：.

56 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2213723, encodeId=45132213e23cd, content=审稿速度:1.0 偏重的研究方向：泌尿系肿瘤 经验分享：很垃圾的期刊，不愧是阿三创办的 写了篇前列腺癌的临床研究，回顾性分析 貌似就一个审稿人，给拒了，理由是建议投稿至泌尿外科或者肿瘤科的期刊 然后编辑就给了拒稿 明明官网写的清清楚楚，泌尿外科和肿瘤学的文章都收，还能以这个理由拒稿 给的审稿人还不是泌尿外科或者肿瘤科的人，编辑部也是极品了 审稿人也是个der，不是你领域的文章你拒绝审稿邀请不就行了，还给我拒稿了，浪费我那么长时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1eff9108850, createdName=ms9000001144988530, createdTime=Sun Jul 07 12:30:45 CST 2024, time=2024-07-07, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1199342, encodeId=fb8b1199342bf, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：普通外科学 经验分享：9月份投稿，12月返修，次年1月接受，2月风出版，**版权就免版面费，人生中第一篇sci,非常激动和感激。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eafe5507087, createdName=ms1000000343499485, createdTime=Fri Mar 04 10:59:07 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188584, encodeId=63ae1188584d3, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ecdd5512474, createdName=ms8000000861535702, createdTime=Thu Jan 27 14:02:15 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101836, encodeId=73f1110183634, content=讨论中局限性怎么撰写？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101835, encodeId=375a110183584, content=是否需要在讨论中说明文章局限性？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080259, encodeId=f4ca1080259c3, content=各位大咖，我投了一篇稿，要求提供伦理委员会证明，有没有模板之类的？谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/bjkbwbHXEDKYj70DA8G0QLwo33kNdOmR0oUwVuP0FibVF8qssNC8nADf0OTkicaMU806LQVe15sPw0bBoVrbQBWg/132, createdBy=63c55215809, createdName=ms3330713541554951, createdTime=Wed Dec 15 10:48:09 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=507298, encodeId=214d50e29847, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：印度杂志，比较好中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=426, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96ff1604274, createdName=xietingfeng124, createdTime=Mon Nov 03 20:12:00 CST 2014, time=2014-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=543696, encodeId=5253543696fc, content=只要能保住SCI源的期刊,就可以了.以后学校采用CiteScore来计算的话,就不用怕了. 一方面CiteScore引用的杂志宽得多,这个杂志肯定在其中,另外,对小杂志有好处,大家差剧没这么大, 希望学校采用CiteScore, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=354, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=Lin_ling, createdTime=Fri Jul 14 18:54:00 CST 2017, time=2017-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=531108, encodeId=a6db5311081d, content=审稿速度:12.0 | 投稿命中率:50.0 经验分享：2016年3月份开始投稿，大修1次，小修1次，2016年年底ACCEPT, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=220, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2019/01/06/7a77f76154188e6264228df7693515cf.jpg, createdBy=cb4a1680684, createdName=xiayu0001, createdTime=Mon Dec 26 21:49:00 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=521934, encodeId=ad9052193462, content=审稿一年了，还是Under review，要等到什么时候啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=410, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11f51627008, createdName=yezhifanfan, createdTime=Mon May 02 15:04:00 CST 2016, time=2016-05-02, status=1, ipAttribution=)]

2021-12-28 ms6000000264964247

讨论中局限性怎么撰写？

47 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2213723, encodeId=45132213e23cd, content=审稿速度:1.0 偏重的研究方向：泌尿系肿瘤 经验分享：很垃圾的期刊，不愧是阿三创办的 写了篇前列腺癌的临床研究，回顾性分析 貌似就一个审稿人，给拒了，理由是建议投稿至泌尿外科或者肿瘤科的期刊 然后编辑就给了拒稿 明明官网写的清清楚楚，泌尿外科和肿瘤学的文章都收，还能以这个理由拒稿 给的审稿人还不是泌尿外科或者肿瘤科的人，编辑部也是极品了 审稿人也是个der，不是你领域的文章你拒绝审稿邀请不就行了，还给我拒稿了，浪费我那么长时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1eff9108850, createdName=ms9000001144988530, createdTime=Sun Jul 07 12:30:45 CST 2024, time=2024-07-07, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1199342, encodeId=fb8b1199342bf, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：普通外科学 经验分享：9月份投稿，12月返修，次年1月接受，2月风出版，**版权就免版面费，人生中第一篇sci,非常激动和感激。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eafe5507087, createdName=ms1000000343499485, createdTime=Fri Mar 04 10:59:07 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188584, encodeId=63ae1188584d3, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ecdd5512474, createdName=ms8000000861535702, createdTime=Thu Jan 27 14:02:15 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101836, encodeId=73f1110183634, content=讨论中局限性怎么撰写？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101835, encodeId=375a110183584, content=是否需要在讨论中说明文章局限性？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080259, encodeId=f4ca1080259c3, content=各位大咖，我投了一篇稿，要求提供伦理委员会证明，有没有模板之类的？谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/bjkbwbHXEDKYj70DA8G0QLwo33kNdOmR0oUwVuP0FibVF8qssNC8nADf0OTkicaMU806LQVe15sPw0bBoVrbQBWg/132, createdBy=63c55215809, createdName=ms3330713541554951, createdTime=Wed Dec 15 10:48:09 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=507298, encodeId=214d50e29847, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：印度杂志，比较好中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=426, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96ff1604274, createdName=xietingfeng124, createdTime=Mon Nov 03 20:12:00 CST 2014, time=2014-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=543696, encodeId=5253543696fc, content=只要能保住SCI源的期刊,就可以了.以后学校采用CiteScore来计算的话,就不用怕了. 一方面CiteScore引用的杂志宽得多,这个杂志肯定在其中,另外,对小杂志有好处,大家差剧没这么大, 希望学校采用CiteScore, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=354, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=Lin_ling, createdTime=Fri Jul 14 18:54:00 CST 2017, time=2017-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=531108, encodeId=a6db5311081d, content=审稿速度:12.0 | 投稿命中率:50.0 经验分享：2016年3月份开始投稿，大修1次，小修1次，2016年年底ACCEPT, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=220, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2019/01/06/7a77f76154188e6264228df7693515cf.jpg, createdBy=cb4a1680684, createdName=xiayu0001, createdTime=Mon Dec 26 21:49:00 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=521934, encodeId=ad9052193462, content=审稿一年了，还是Under review，要等到什么时候啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=410, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11f51627008, createdName=yezhifanfan, createdTime=Mon May 02 15:04:00 CST 2016, time=2016-05-02, status=1, ipAttribution=)]

2021-12-27 学医的彭于晏

是否需要在讨论中说明文章局限性？

51 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2213723, encodeId=45132213e23cd, content=审稿速度:1.0 偏重的研究方向：泌尿系肿瘤 经验分享：很垃圾的期刊，不愧是阿三创办的 写了篇前列腺癌的临床研究，回顾性分析 貌似就一个审稿人，给拒了，理由是建议投稿至泌尿外科或者肿瘤科的期刊 然后编辑就给了拒稿 明明官网写的清清楚楚，泌尿外科和肿瘤学的文章都收，还能以这个理由拒稿 给的审稿人还不是泌尿外科或者肿瘤科的人，编辑部也是极品了 审稿人也是个der，不是你领域的文章你拒绝审稿邀请不就行了，还给我拒稿了，浪费我那么长时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1eff9108850, createdName=ms9000001144988530, createdTime=Sun Jul 07 12:30:45 CST 2024, time=2024-07-07, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1199342, encodeId=fb8b1199342bf, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：普通外科学 经验分享：9月份投稿，12月返修，次年1月接受，2月风出版，**版权就免版面费，人生中第一篇sci,非常激动和感激。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eafe5507087, createdName=ms1000000343499485, createdTime=Fri Mar 04 10:59:07 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188584, encodeId=63ae1188584d3, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ecdd5512474, createdName=ms8000000861535702, createdTime=Thu Jan 27 14:02:15 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101836, encodeId=73f1110183634, content=讨论中局限性怎么撰写？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101835, encodeId=375a110183584, content=是否需要在讨论中说明文章局限性？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080259, encodeId=f4ca1080259c3, content=各位大咖，我投了一篇稿，要求提供伦理委员会证明，有没有模板之类的？谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/bjkbwbHXEDKYj70DA8G0QLwo33kNdOmR0oUwVuP0FibVF8qssNC8nADf0OTkicaMU806LQVe15sPw0bBoVrbQBWg/132, createdBy=63c55215809, createdName=ms3330713541554951, createdTime=Wed Dec 15 10:48:09 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=507298, encodeId=214d50e29847, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：印度杂志，比较好中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=426, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96ff1604274, createdName=xietingfeng124, createdTime=Mon Nov 03 20:12:00 CST 2014, time=2014-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=543696, encodeId=5253543696fc, content=只要能保住SCI源的期刊,就可以了.以后学校采用CiteScore来计算的话,就不用怕了. 一方面CiteScore引用的杂志宽得多,这个杂志肯定在其中,另外,对小杂志有好处,大家差剧没这么大, 希望学校采用CiteScore, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=354, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=Lin_ling, createdTime=Fri Jul 14 18:54:00 CST 2017, time=2017-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=531108, encodeId=a6db5311081d, content=审稿速度:12.0 | 投稿命中率:50.0 经验分享：2016年3月份开始投稿，大修1次，小修1次，2016年年底ACCEPT, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=220, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2019/01/06/7a77f76154188e6264228df7693515cf.jpg, createdBy=cb4a1680684, createdName=xiayu0001, createdTime=Mon Dec 26 21:49:00 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=521934, encodeId=ad9052193462, content=审稿一年了，还是Under review，要等到什么时候啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=410, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11f51627008, createdName=yezhifanfan, createdTime=Mon May 02 15:04:00 CST 2016, time=2016-05-02, status=1, ipAttribution=)]

2021-12-15 ms3330713541554951

各位大咖，我投了一篇稿，要求提供伦理委员会证明，有没有模板之类的？谢谢

54 0

[GetPortalCommentsPageByObjectIdResponse(id=2213723, encodeId=45132213e23cd, content=审稿速度:1.0 偏重的研究方向：泌尿系肿瘤 经验分享：很垃圾的期刊，不愧是阿三创办的 写了篇前列腺癌的临床研究，回顾性分析 貌似就一个审稿人，给拒了，理由是建议投稿至泌尿外科或者肿瘤科的期刊 然后编辑就给了拒稿 明明官网写的清清楚楚，泌尿外科和肿瘤学的文章都收，还能以这个理由拒稿 给的审稿人还不是泌尿外科或者肿瘤科的人，编辑部也是极品了 审稿人也是个der，不是你领域的文章你拒绝审稿邀请不就行了，还给我拒稿了，浪费我那么长时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1eff9108850, createdName=ms9000001144988530, createdTime=Sun Jul 07 12:30:45 CST 2024, time=2024-07-07, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1199342, encodeId=fb8b1199342bf, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：普通外科学 经验分享：9月份投稿，12月返修，次年1月接受，2月风出版，**版权就免版面费，人生中第一篇sci,非常激动和感激。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eafe5507087, createdName=ms1000000343499485, createdTime=Fri Mar 04 10:59:07 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188584, encodeId=63ae1188584d3, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ecdd5512474, createdName=ms8000000861535702, createdTime=Thu Jan 27 14:02:15 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101836, encodeId=73f1110183634, content=讨论中局限性怎么撰写？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101835, encodeId=375a110183584, content=是否需要在讨论中说明文章局限性？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080259, encodeId=f4ca1080259c3, content=各位大咖，我投了一篇稿，要求提供伦理委员会证明，有没有模板之类的？谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/bjkbwbHXEDKYj70DA8G0QLwo33kNdOmR0oUwVuP0FibVF8qssNC8nADf0OTkicaMU806LQVe15sPw0bBoVrbQBWg/132, createdBy=63c55215809, createdName=ms3330713541554951, createdTime=Wed Dec 15 10:48:09 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=507298, encodeId=214d50e29847, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：印度杂志，比较好中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=426, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96ff1604274, createdName=xietingfeng124, createdTime=Mon Nov 03 20:12:00 CST 2014, time=2014-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=543696, encodeId=5253543696fc, content=只要能保住SCI源的期刊,就可以了.以后学校采用CiteScore来计算的话,就不用怕了. 一方面CiteScore引用的杂志宽得多,这个杂志肯定在其中,另外,对小杂志有好处,大家差剧没这么大, 希望学校采用CiteScore, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=354, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=Lin_ling, createdTime=Fri Jul 14 18:54:00 CST 2017, time=2017-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=531108, encodeId=a6db5311081d, content=审稿速度:12.0 | 投稿命中率:50.0 经验分享：2016年3月份开始投稿，大修1次，小修1次，2016年年底ACCEPT, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=220, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2019/01/06/7a77f76154188e6264228df7693515cf.jpg, createdBy=cb4a1680684, createdName=xiayu0001, createdTime=Mon Dec 26 21:49:00 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=521934, encodeId=ad9052193462, content=审稿一年了，还是Under review，要等到什么时候啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=410, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11f51627008, createdName=yezhifanfan, createdTime=Mon May 02 15:04:00 CST 2016, time=2016-05-02, status=1, ipAttribution=)]

2014-11-03 xietingfeng124

审稿速度:2.0 | 投稿命中率:75.0
经验分享：印度杂志，比较好中

426 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2213723, encodeId=45132213e23cd, content=审稿速度:1.0 偏重的研究方向：泌尿系肿瘤 经验分享：很垃圾的期刊，不愧是阿三创办的 写了篇前列腺癌的临床研究，回顾性分析 貌似就一个审稿人，给拒了，理由是建议投稿至泌尿外科或者肿瘤科的期刊 然后编辑就给了拒稿 明明官网写的清清楚楚，泌尿外科和肿瘤学的文章都收，还能以这个理由拒稿 给的审稿人还不是泌尿外科或者肿瘤科的人，编辑部也是极品了 审稿人也是个der，不是你领域的文章你拒绝审稿邀请不就行了，还给我拒稿了，浪费我那么长时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1eff9108850, createdName=ms9000001144988530, createdTime=Sun Jul 07 12:30:45 CST 2024, time=2024-07-07, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1199342, encodeId=fb8b1199342bf, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：普通外科学 经验分享：9月份投稿，12月返修，次年1月接受，2月风出版，**版权就免版面费，人生中第一篇sci,非常激动和感激。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eafe5507087, createdName=ms1000000343499485, createdTime=Fri Mar 04 10:59:07 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188584, encodeId=63ae1188584d3, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ecdd5512474, createdName=ms8000000861535702, createdTime=Thu Jan 27 14:02:15 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101836, encodeId=73f1110183634, content=讨论中局限性怎么撰写？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101835, encodeId=375a110183584, content=是否需要在讨论中说明文章局限性？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080259, encodeId=f4ca1080259c3, content=各位大咖，我投了一篇稿，要求提供伦理委员会证明，有没有模板之类的？谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/bjkbwbHXEDKYj70DA8G0QLwo33kNdOmR0oUwVuP0FibVF8qssNC8nADf0OTkicaMU806LQVe15sPw0bBoVrbQBWg/132, createdBy=63c55215809, createdName=ms3330713541554951, createdTime=Wed Dec 15 10:48:09 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=507298, encodeId=214d50e29847, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：印度杂志，比较好中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=426, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96ff1604274, createdName=xietingfeng124, createdTime=Mon Nov 03 20:12:00 CST 2014, time=2014-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=543696, encodeId=5253543696fc, content=只要能保住SCI源的期刊,就可以了.以后学校采用CiteScore来计算的话,就不用怕了. 一方面CiteScore引用的杂志宽得多,这个杂志肯定在其中,另外,对小杂志有好处,大家差剧没这么大, 希望学校采用CiteScore, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=354, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=Lin_ling, createdTime=Fri Jul 14 18:54:00 CST 2017, time=2017-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=531108, encodeId=a6db5311081d, content=审稿速度:12.0 | 投稿命中率:50.0 经验分享：2016年3月份开始投稿，大修1次，小修1次，2016年年底ACCEPT, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=220, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2019/01/06/7a77f76154188e6264228df7693515cf.jpg, createdBy=cb4a1680684, createdName=xiayu0001, createdTime=Mon Dec 26 21:49:00 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=521934, encodeId=ad9052193462, content=审稿一年了，还是Under review，要等到什么时候啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=410, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11f51627008, createdName=yezhifanfan, createdTime=Mon May 02 15:04:00 CST 2016, time=2016-05-02, status=1, ipAttribution=)]

2017-07-14 Lin_ling

只要能保住SCI源的期刊,就可以了.以后学校采用CiteScore来计算的话,就不用怕了. 一方面CiteScore引用的杂志宽得多,这个杂志肯定在其中,另外,对小杂志有好处,大家差剧没这么大, 希望学校采用CiteScore

354 0

[GetPortalCommentsPageByObjectIdResponse(id=2213723, encodeId=45132213e23cd, content=审稿速度:1.0 偏重的研究方向：泌尿系肿瘤 经验分享：很垃圾的期刊，不愧是阿三创办的 写了篇前列腺癌的临床研究，回顾性分析 貌似就一个审稿人，给拒了，理由是建议投稿至泌尿外科或者肿瘤科的期刊 然后编辑就给了拒稿 明明官网写的清清楚楚，泌尿外科和肿瘤学的文章都收，还能以这个理由拒稿 给的审稿人还不是泌尿外科或者肿瘤科的人，编辑部也是极品了 审稿人也是个der，不是你领域的文章你拒绝审稿邀请不就行了，还给我拒稿了，浪费我那么长时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1eff9108850, createdName=ms9000001144988530, createdTime=Sun Jul 07 12:30:45 CST 2024, time=2024-07-07, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1199342, encodeId=fb8b1199342bf, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：普通外科学 经验分享：9月份投稿，12月返修，次年1月接受，2月风出版，**版权就免版面费，人生中第一篇sci,非常激动和感激。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eafe5507087, createdName=ms1000000343499485, createdTime=Fri Mar 04 10:59:07 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188584, encodeId=63ae1188584d3, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ecdd5512474, createdName=ms8000000861535702, createdTime=Thu Jan 27 14:02:15 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101836, encodeId=73f1110183634, content=讨论中局限性怎么撰写？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101835, encodeId=375a110183584, content=是否需要在讨论中说明文章局限性？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080259, encodeId=f4ca1080259c3, content=各位大咖，我投了一篇稿，要求提供伦理委员会证明，有没有模板之类的？谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/bjkbwbHXEDKYj70DA8G0QLwo33kNdOmR0oUwVuP0FibVF8qssNC8nADf0OTkicaMU806LQVe15sPw0bBoVrbQBWg/132, createdBy=63c55215809, createdName=ms3330713541554951, createdTime=Wed Dec 15 10:48:09 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=507298, encodeId=214d50e29847, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：印度杂志，比较好中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=426, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96ff1604274, createdName=xietingfeng124, createdTime=Mon Nov 03 20:12:00 CST 2014, time=2014-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=543696, encodeId=5253543696fc, content=只要能保住SCI源的期刊,就可以了.以后学校采用CiteScore来计算的话,就不用怕了. 一方面CiteScore引用的杂志宽得多,这个杂志肯定在其中,另外,对小杂志有好处,大家差剧没这么大, 希望学校采用CiteScore, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=354, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=Lin_ling, createdTime=Fri Jul 14 18:54:00 CST 2017, time=2017-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=531108, encodeId=a6db5311081d, content=审稿速度:12.0 | 投稿命中率:50.0 经验分享：2016年3月份开始投稿，大修1次，小修1次，2016年年底ACCEPT, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=220, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2019/01/06/7a77f76154188e6264228df7693515cf.jpg, createdBy=cb4a1680684, createdName=xiayu0001, createdTime=Mon Dec 26 21:49:00 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=521934, encodeId=ad9052193462, content=审稿一年了，还是Under review，要等到什么时候啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=410, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11f51627008, createdName=yezhifanfan, createdTime=Mon May 02 15:04:00 CST 2016, time=2016-05-02, status=1, ipAttribution=)]

2016-12-26 xiayu0001

审稿速度:12.0 | 投稿命中率:50.0
经验分享：2016年3月份开始投稿，大修1次，小修1次，2016年年底ACCEPT

220 0

[GetPortalCommentsPageByObjectIdResponse(id=2213723, encodeId=45132213e23cd, content=审稿速度:1.0 偏重的研究方向：泌尿系肿瘤 经验分享：很垃圾的期刊，不愧是阿三创办的 写了篇前列腺癌的临床研究，回顾性分析 貌似就一个审稿人，给拒了，理由是建议投稿至泌尿外科或者肿瘤科的期刊 然后编辑就给了拒稿 明明官网写的清清楚楚，泌尿外科和肿瘤学的文章都收，还能以这个理由拒稿 给的审稿人还不是泌尿外科或者肿瘤科的人，编辑部也是极品了 审稿人也是个der，不是你领域的文章你拒绝审稿邀请不就行了，还给我拒稿了，浪费我那么长时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1eff9108850, createdName=ms9000001144988530, createdTime=Sun Jul 07 12:30:45 CST 2024, time=2024-07-07, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1199342, encodeId=fb8b1199342bf, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：普通外科学 经验分享：9月份投稿，12月返修，次年1月接受，2月风出版，**版权就免版面费，人生中第一篇sci,非常激动和感激。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eafe5507087, createdName=ms1000000343499485, createdTime=Fri Mar 04 10:59:07 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188584, encodeId=63ae1188584d3, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ecdd5512474, createdName=ms8000000861535702, createdTime=Thu Jan 27 14:02:15 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101836, encodeId=73f1110183634, content=讨论中局限性怎么撰写？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101835, encodeId=375a110183584, content=是否需要在讨论中说明文章局限性？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080259, encodeId=f4ca1080259c3, content=各位大咖，我投了一篇稿，要求提供伦理委员会证明，有没有模板之类的？谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/bjkbwbHXEDKYj70DA8G0QLwo33kNdOmR0oUwVuP0FibVF8qssNC8nADf0OTkicaMU806LQVe15sPw0bBoVrbQBWg/132, createdBy=63c55215809, createdName=ms3330713541554951, createdTime=Wed Dec 15 10:48:09 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=507298, encodeId=214d50e29847, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：印度杂志，比较好中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=426, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96ff1604274, createdName=xietingfeng124, createdTime=Mon Nov 03 20:12:00 CST 2014, time=2014-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=543696, encodeId=5253543696fc, content=只要能保住SCI源的期刊,就可以了.以后学校采用CiteScore来计算的话,就不用怕了. 一方面CiteScore引用的杂志宽得多,这个杂志肯定在其中,另外,对小杂志有好处,大家差剧没这么大, 希望学校采用CiteScore, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=354, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=Lin_ling, createdTime=Fri Jul 14 18:54:00 CST 2017, time=2017-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=531108, encodeId=a6db5311081d, content=审稿速度:12.0 | 投稿命中率:50.0 经验分享：2016年3月份开始投稿，大修1次，小修1次，2016年年底ACCEPT, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=220, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2019/01/06/7a77f76154188e6264228df7693515cf.jpg, createdBy=cb4a1680684, createdName=xiayu0001, createdTime=Mon Dec 26 21:49:00 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=521934, encodeId=ad9052193462, content=审稿一年了，还是Under review，要等到什么时候啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=410, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11f51627008, createdName=yezhifanfan, createdTime=Mon May 02 15:04:00 CST 2016, time=2016-05-02, status=1, ipAttribution=)]

2016-05-02 yezhifanfan

审稿一年了，还是Under review，要等到什么时候啊

410 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务